JWA
CNCR

JFS Wealth Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

JFS Wealth Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$5K – 581
2020
Q3 		$5K Hold
200
– – ﹤0.01% 442
2020
Q2 		$5K Buy
+200
New +$4.91K ﹤0.01% 427

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LWPC
Legacy Wealth Partners (California) Calabasas, California $180M AUM 48.85% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JFS Wealth Advisors's CNCR Position: Q4 2020 in Review

JFS Wealth Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2020, closing a stake of 200 shares — an estimated $5K sold.

JFS Wealth Advisors first reported a position in CNCR in Q2 2020 and held it in 2 quarters. The position peaked at $5K in Q3 2020. 22 funds tracked by Wall St. Rank hold CNCR as of Q4 2020.

  • JFS Wealth Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2020 after selling out during the quarter.
  • JFS Wealth Advisors sold 200 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2020, an estimated $5K.
  • JFS Wealth Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2020 and held it in 2 quarters.
  • JFS Wealth Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $5K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2020.

Based on JFS Wealth Advisors's 13F filing for Q4 2020, filed 1 Feb 2021.